| Name | RepSox |
| Description | RepSox (ALK5 Inhibitor II) is a TGFβR-1/ALK5 inhibitor that selectively inhibits the binding of ATP to ALK5 and the autophosphorylation of ALK5 (IC50=23/4 nM). RepSox induces adipogenesis in MEFs cells. |
| Cell Research | RepSox is dissolved in DMSO and stored, and then diluted with appropriate media (DMSO 1%) before use[1]. To test anti-TGF-β activity of compounds, HepG2 cells are seeded in 96 well microplates at a concentration of 35000 cells per well in 200 μL of serum-containing medium. The microplates are then placed for 24 h in a cell incubator at 37°C, 5% CO2 atm. RepSox dissolved in DMSO are then added at concentrations of 50 nM to 10 μM (final concentration of DMSO 1%) for 30 min prior to the addition of recombinant TGF-β (1 ng/mL). After an overnight incubation, the cells are washed with PBS and lysed by addition of 10 μL of passive lysis buffer. Inhibition of luciferase activity relative to control groups is used as a measure of compound activity. A concentration?response curve is constructed from which an IC50 value is determined graphically[1]. |
| Kinase Assay | The kinase domain of ALK5 is cloned by PCR and expressed in a baculovirus/Sf9 cells system. The protein is 6-His tagged in the C terminus and purified by affinity chromatography using a Ni2+column, and the obtained material is used to assess compound activity in an autophosphorylation assay. Purified enzyme (10 nM) is incubated in 50 μL of Tris buffer (Tris 50 mM, pH 7.4; NaCl, 100 mM; MgCl2, 5 mM; MnCl2, 5 mM; and DTT, 10 mM). The enzyme is preincubated with different concentrations of RepSox (0.1% DMSO final concentration in the test) for 10 min at 37°C. The reaction is then initiated by the addition of 3 μM ATP (0.5 μCi γ-33P-ATP). After 15 min at 37°C, phosphorylation is stopped by the addition of SDS?PAGE sample buffer (50 mM Tris-HCl, pH 6.9, 2.5% glycerol, 1% SDS, and 5% β-mercaptoethanol). The samples are boiled for 5 min at 95°C and run on a 12% SDS?PAGE. Dried gels are exposed to a phosphor screen overnight. ALK5 autophosphorylation is quantified using a Storm imaging system[1]. |
| In vitro | METHODS: Mouse embryonic fibroblast MEFs were treated with RepSox (10 µM) for 10 days and cellular lipids were detected using oil red O staining.
RESULTS: Many adipocyte-like cells appeared in RepSox-treated MEFs, and oil red O staining of lipid droplets confirmed adipocyte differentiation. [1]
METHODS: Sheep fibroblasts were treated with RepSox (10-25 nM) for 3 days, and cell morphology was observed using a microscope.
RESULTS: After three days of RepSox treatment, sheep fibroblasts acquired a significantly different morphology and changed from a spindle shape to an elongated shape with more clusters. [2] |
| In vivo | METHODS: To test the effect on the differentiation of EGCs from intestinal glial cells, RepSox (3-10 mg/kg in 0.5% CMC-Na) was injected intraperitoneally to GFAP-Cre:Rosa26-tdTomato mice once daily for two weeks.
RESULTS: RepSox promotes the conversion of EGCs into neurons and improves gastrointestinal motility in vivo. [3]
METHODS: To detect anti-tumor activity in vivo, RepSox (5-20 mg/kg) was injected intraperitoneally into a nude mouse model bearing osteosarcoma 143B every two days for three weeks.
RESULTS: RepSox effectively inhibited the growth of osteosarcoma and had low toxicity in nude mice. [4] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (17.4 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 51 mg/mL (177.5 mM), Sonication is recommended.
|
| Keywords | Transforming growth factor beta receptors | TGFβR1 | TGF-β/Smad | TGF-β Receptor | TGFβ | TGFbeta/Smad | TGF-beta | TGFbeta | TGF-b/Smad | TGFb | Smad | SJN-2511 | SJN2511 | RepSox | Inhibitor | inhibit | E616452 | E 616452 | ALK5 |
| Inhibitors Related | Entrectinib | Lorlatinib | Monocrotaline | DMH-1 | Hydrochlorothiazide | Crizotinib | Chromenone 1 | Ceritinib | Pirfenidone | A 83-01 | Galunisertib | Alantolactone |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Obesity Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library | TGF-beta/Smad Compound Library |
United States
